Interleukin Related Inhibitor

Interleukin Related Inhibitors (616):

Cat. No.	Product Name	Effect	Purity

HY-154629

Sesame Oil	Inhibitor	98.2%
Sesame Oil is a vegetable oil. Sesame Oil can be extracted from the seeds of Sesamum indicum L. Sesame Oil decreases NF-κB, aspartate aminotransferase, alanine aminotransferase, IL-1β, IL-4 and nitric oxide. Sesame Oil has antitumor activity against malignant melanoma. Sesame Oil has protective effects against liver damage caused by various agents such as Cisplatin (HY-17394) and Acetaminophen (HY-66005). Sesame Oil shows antinociceptive and anti-inflammatory activities.

HY-P9950

Omalizumab	Inhibitor	99.70%
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a K_D of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a K_D of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research. The component ratio of this product is Active ingredient : Excipients = 1:1.3-1:1.5.

HY-153793A

Alcudacigib TFA	Inhibitor	99.72%
Alcudacigib (ASP1570; DGKζ-IN-1) TFA is an orally active diacylglycerol kinase ζ (DGKζ) inhibitor, with an IC₅₀ of 4.7 nM against human DGKζ and an IC₅₀ of 3.0 nM against mouse DGKζ. Alcudacigib TFA selectively inhibits the kinase activity of DGKζ and induces proteasome-dependent degradation of DGKζ protein. Alcudacigib TFA enhances the anti-tumor functions of T cells and NK cells. Alcudacigib TFA can be used for the research of advanced/metastatic solid tumors.

HY-178037A

TLR9 antagonist 1 diformate	Inhibitor
TLR9 antagonist 1 diformate is a selective hTLR9 antagonist with an IC₅₀ of 0.1 nM against hTLR9. TLR9 antagonist 1 diformate exhibits favorable pharmacokinetic and pharmacodynamic properties. TLR9 antagonist 1 diformate can be used in the research of systemic lupus erythematosus.

HY-P991797

Anti-Mouse IL-17A Antibody (BZN035)	Inhibitor
Anti-Mouse IL-17A Antibody (BZN035) targets mouse IL-17A that can neutralize IL-17 in mice. Recommend Isotype Controls: Mouse IgG2a kappa, Isotype Control (HY-P99978).

HY-17007

Saquinavir	Inhibitor	99.77%
Saquinavir (Ro 31-8959) is an orally active HIV protease inhibitor that can be used in the research of AIDS. Saquinavir also has anti-inflammatory activity and can induce apoptosis of human red blood cells.

HY-108810

Canakinumab	Inhibitor	99.64%
Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC₅₀ values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin.

HY-163731

EGR-1-IN-1	Inhibitor	99.07%
EGR-1-IN-1 is a EGR-1 inhibitor with an IC₅₀ of 1.86 μM. EGR-1-IN-1 binds to the zinc finger DNA-binding domain of EGR-1 and promotes the dissociation of the EGR-1-DNA complex. EGR-1-IN-1 reduces the mRNA expression levels of EGR-1-regulated inflammatory genes induced by TNFα. EGR-1-IN-1 alleviates atopic dermatitis-like lesions in the ear skin of mice. EGR-1-IN-1 serves as a lead compound for the development of targeted compounds for inflammatory skin diseases. EGR-1-IN-1 can be used in studies related to atopic dermatitis.

HY-P99162

Nemolizumab	Inhibitor	99.70%
Nemolizumab (CIM331) is a humanized monoclonal antibody that targets the human interleukin-31 receptor a, preventing interleukin-31 (IL-31) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD).

HY-N0890

Tubeimoside I	Inhibitor	99.96%
Tubeimoside I is an orally active HSPD1 inhibitor. Tubeimoside I inhibits NF-κB, MAPK, as well as regulates eNOS-VEGF. Tubeimoside I induces cytoprotective Autophagy via an Akt-mediated pathway. Tubeimoside I inhibits proinflammatory cytokine (IL-6 and IL-1β) production. Tubeimoside I exhibits anti-inflammatory activities. Tubeimoside I promotes angiogenesis and improves sepsis symptoms. Tubeimoside I is used in the research of inflammatory diseases, various cancers, sepsis and ischemic diseases.

HY-N0405

Orientin	Inhibitor	99.89%
Orientin is a neuroprotective agentinhibits which has anti-inflammation, anti-oxidative, anti-tumor, and cardio protection properties. Orientin inhibits the levels of IL-6, IL-1β and TNF-α. Orientin increases IL-10 level. Orientin exhibits neuroprotective effect by inhibits TLR4 and NF-kappa B signaling pathway. Orientin can used in study neuropathic pain.

HY-P991028

Surovatamig	Inhibitor	99.89%
Surovatamig (AZD0486; TNB-486) is a fully human anti-CD19/CD3 IgG4 bispecific antibody. Surovatamig triggers T cell activation, releases cytotoxic granules, and induces T cell-dependent cellular cytotoxicity and tumor cell lysis. Surovatamig can reduces release of pro-inflammatory cytokines including IL-2, IFNγ, TNF. Surovatamig can be used for the research of cancer, such as B cell non-Hodgkin lymphoma.

HY-P9925

Brodalumab	Inhibitor	99.18%
Brodalumab (AMG 827) is a human anti-interleukin-17-receptor IgG2 monoclonal antibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis.

HY-P99550

Tozorakimab	Inhibitor	98.82%
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease.

HY-P99673

Itepekimab	Inhibitor	99.496%
Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD).

HY-P990211

Anti-Mouse IL-6R Antibody (15A7)	Inhibitor	99.79%
Anti-Mouse IL-6R Antibody (15A7) is a rat-derived anti-mouse IL-6R IgG2b κ type antibody inhibitor. Anti-Mouse IL-6R Antibody (15A7) blocks IL-6 binding to IL-6Rα and inhibits both IL-6 classic and trans-signaling. Anti-Mouse IL-6R Antibody (15A7) can be used for the researches of cancer and inflammation, such as triple-negative breast cancer.

HY-P99519

Vixarelimab	Inhibitor
Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) receptor β subunit monoclonal antibody. Vixarelimab inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash.

HY-P990222

Anti-Mouse/Rat IL-17A Antibody (17F3)	Inhibitor	99.41%
Anti-Mouse/Rat IL-17A Antibody (17F3) is a mouse-derived IgG1κ type antibody inhibitor, targeting to mouse and rat IL-17A. Anti-Mouse IL-17A Antibody (17F3) can neutralize IL-17. Anti-Mouse/Rat IL-17A Antibody (17F3) can be used for the researches of infection, immunology and metabolic disease, such as M.intracellulare infection and diabetes.

HY-P3211A

Nangibotide TFA	Inhibitor	99.86%
Nangibotide TFA (LR12 TFA) is a synthetic peptide and TREM-1 receptor inhibitor. Nangibotide TFA inhibits NF-κB and NLRP3 inflammasome activation and reduces the release of pro-inflammatory factors (such as IL-1β, IL-8). Nangibotide TFA inhibits Apoptosis. Nangibotide TFA reduces excessive inflammatory responses and protects tissues (liver, lung) from damage. Nangibotide TFA can be used in the researches for myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure.

HY-W110551

2-Methacryloyloxyethyl phosphorylcholine	Inhibitor	99.68%
2-Methacryloyloxyethyl phosphorylcholine is a polymer monomer containing a phospholipid polar group. 2-Methacryloyloxyethyl phosphorylcholine polymers modify the surface properties of materials and reduce protein-surface interactions, reduce IL-8 production, inhibit cell, Staphylococcus aureus, and Porphyromonas gingivalis adhesion. 2-Methacryloyloxyethyl phosphorylcholine is used in the study of medical device-associated infections, periodontitis, and dental caries.

Name
Email *

	Sorry, but the email address you supplied was invalid.